These findings underscore the potential of SGLT2 inhibitors to modulate critical intracellular pathways involved in myocardial energetics and remodeling, offering mechanistic support for their clinical efficacy across diverse heart failure phenotypes [12]. The gene discussed is SLC5A2; the disease is heart failure.